Immunovant Stock Performance
| IMVT Stock | USD 26.24 1.11 4.06% |
On a scale of 0 to 100, Immunovant holds a performance score of 14. The company retains a Market Volatility (i.e., Beta) of -0.2, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Immunovant are expected to decrease at a much lower rate. During the bear market, Immunovant is likely to outperform the market. Please check Immunovant's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Immunovant's current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immunovant are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Immunovant unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.94) | Five Day Return (2.51) | Year To Date Return 0.35 | Ten Year Return 161.31 | All Time Return 161.31 |
1 | Disposition of 2520 shares by Jay Stout of Immunovant at 19.03 subject to Rule 16b-3 | 10/22/2025 |
2 | Immunovant Soars 14.6 percent Ahead of Q3 Results | 10/31/2025 |
3 | Will Immunovant Inc. stock outperform value stocks - Trade Exit Summary Weekly Breakout Watchlists - newser.com | 11/19/2025 |
4 | Disposition of 2375 shares by Gloria Melanie of Immunovant at 23.97 subject to Rule 16b-3 | 11/20/2025 |
5 | Disposition of 1909 shares by Hughes Douglas J. of Immunovant at 23.96 subject to Rule 16b-3 | 12/01/2025 |
6 | Roivant Signals Major Pipeline Momentum With Accelerated Timelines | 12/11/2025 |
7 | Acquisition by Roivant Sciences Ltd. of 16666666 shares of Immunovant at 21.0 subject to Rule 16b-3 | 12/12/2025 |
8 | Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 247 Wall St. | 12/17/2025 |
9 | Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by 350 Million | 12/18/2025 |
10 | Disposition of 2284 shares by Van Tuyl Christopher of Immunovant at 27.38 subject to Rule 16b-3 | 12/19/2025 |
11 | How Investors Are Reacting To Immunovant 550 Million Follow-On Equity Raise And Dilution | 12/22/2025 |
12 | Acquisition by Van Tuyl Christopher of 71531 shares of Immunovant at 15.2 subject to Rule 16b-3 | 12/31/2025 |
13 | Disposition of tradable shares by Jay Stout of Immunovant at 26.92 subject to Rule 16b-3 | 01/07/2026 |
14 | Truist Lifts Immunovant PT to 22 on Updated 2026 Financial Modeling | 01/12/2026 |
| Begin Period Cash Flow | 635.4 M | |
| Total Cashflows From Investing Activities | -759 K | |
| Free Cash Flow | -376.6 M |
Immunovant | Build AI portfolio with Immunovant Stock |
Immunovant Relative Risk vs. Return Landscape
If you would invest 1,922 in Immunovant on October 18, 2025 and sell it today you would earn a total of 813.00 from holding Immunovant or generate 42.3% return on investment over 90 days. Immunovant is currently generating 0.6381% in daily expected returns and assumes 3.5116% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Immunovant, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunovant Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunovant's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunovant, and traders can use it to determine the average amount a Immunovant's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1817
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMVT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Immunovant is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunovant by adding it to a well-diversified portfolio.
Immunovant Fundamentals Growth
Immunovant Stock prices reflect investors' perceptions of the future prospects and financial health of Immunovant, and Immunovant fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunovant Stock performance.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | 4.52 B | ||||
| Shares Outstanding | 201.48 M | ||||
| Price To Book | 10.08 X | ||||
| EBITDA | (437.77 M) | ||||
| Net Income | (413.84 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 98 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 2.98 X | ||||
| Cash Flow From Operations | (375.87 M) | ||||
| Earnings Per Share | (2.82) X | ||||
| Market Capitalization | 5.24 B | ||||
| Total Asset | 776.22 M | ||||
| Retained Earnings | (1.24 B) | ||||
| Working Capital | 698.89 M | ||||
About Immunovant Performance
Assessing Immunovant's fundamental ratios provides investors with valuable insights into Immunovant's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Immunovant is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.50) | |
| Return On Capital Employed | (0.71) | (0.68) | |
| Return On Assets | (0.48) | (0.50) | |
| Return On Equity | (0.67) | (0.64) |
Things to note about Immunovant performance evaluation
Checking the ongoing alerts about Immunovant for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunovant help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunovant appears to be risky and price may revert if volatility continues | |
| Immunovant has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (413.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (375.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Immunovant has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Truist Lifts Immunovant PT to 22 on Updated 2026 Financial Modeling |
- Analyzing Immunovant's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunovant's stock is overvalued or undervalued compared to its peers.
- Examining Immunovant's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunovant's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunovant's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunovant's stock. These opinions can provide insight into Immunovant's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.